SLC5A2 and diabetic cardiomyopathy: While the goal of that work was to determine the effect of SGLT2 inhibition in a model of diabetic cardiomyopathy caused by diet excess, a noteworthy finding was that pro-metabolic programming of the heart by the SGLT2 inhibitor also occurred in non-diabetic control mice, indicating that it was independent of diabetes [12].